Interventional device developer Boston Scientific said it will provide lead support for an extension of the Strategic Transcatheter Evaluation of New Therapies (STENT) drug-eluting stent registry to study the effects of late stent thrombosis in drug-eluting stents.
The multicenter registry will begin enrolling the approximately 10,000 patients for the study in early 2007, according to Boston Scientific of Natick, MA.
By AuntMinnie.com staff writers
October 24, 2006
Related Reading
Boston nets CE mark, October 16, 2006
Boston Scientific taps Japp, October 11, 2006
Boston Scientific introduces FlexView, September 20, 2006
Boston Scientific reaches halfway point in drug-eluting stent trial, August 31, 2006
Boston Scientific posts powerful Q2 sales, July 27, 2006
Copyright © 2006 AuntMinnie.com